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Objective: Lower extremity deep vein thrombosis is often isolated to the sinusoidal veins draining the gastrocnemius and
soleus muscles. The purpose of this study was to establish the incidence rate of propagation of isolated gastrocnemius and
soleal vein thrombosis (IGSVT) into the deep veins of the calf and thigh.
Methods: All patients who were referred for color flow duplex ultrasonography (CFDU) for suspected deep vein
thrombosis were prospectively evaluated for IGSVT. Patients with IGSVT received no systemic anticoagulation therapy
and underwent serial CFDU at 5, 9, 14, 30, and 90 days after recruitment. The incidence and extent of IGSVT
propagation were noted. Factors predictive of IGSVT extension were sought, including age, gender, side, symptoms,
ambulatory status, and the presence of comorbid illness, including cardiac disease, cancer, hypercoagulable states, recent
surgery or trauma, and previous venous disease.
Results: One hundred thirty-five limbs with IGSVT were studied for 3 months, and 16.3% of cases with IGSVT extended
the thrombus to the level of the adjacent tibial, or peroneal, veins or higher. Only 3% of the cases with IGSVT propagated
as cephalad as the popliteal vein, and 90.9% of IGSVT propagation occurred within 2 weeks of CFDU diagnosis. No
IGSVT propagated to the level of the popliteal vein beyond 2 weeks from the time of CFDU diagnosis. No IGSVT
extended into the deep veins of the thigh. By the end of the 3-month study period, 45.9% of thrombi had completely
resolved. Only the presence of cancer was prognostic for IGSVT progression.
Conclusion: During the 3-month study period, the short-term incidence rate of untreated IGSVT propagation to the level
of the popliteal vein, even in the presence of cancer, was only 3%. Follow-up imaging to detect IGSVT propagation
beyond 2 weeks from the time of diagnosis may not be necessary. (J Vasc Surg 2003;37:523-7.)
Conflicting data have been reported by a number of
studies regarding the incidence rate of propagation of calf
vein thrombosis (CVT) into the proximal deep veins of the
leg.1-13 A 20% incidence rate of propagation is widely
quoted.14 However, as color flow duplex ultrasonography
(CFDU) has evolved to become the imaging method of
choice for investigating CVT, CVT isolated to the veins
draining the gastrocnemius and soleal muscles is being
recognized with greater frequency.3,5,7,9,15,16
Traditionally, studies involving CVT have not differen-
tiated between the paired venae commitantes that parallel
the tibial and peroneal arteries and the short, unnamed
sinusoidal veins that directly drain the gastrocnemius and
soleal muscles.1-9,11-13 However, with improved resolution
of CFDU and greater attention to scanning for thrombosis
involving the gastrocnemius and soleal veins, up to 40% of
symptomatic isolated CVT appear to be isolated to the
veins that drain the gastrocnemius and soleal muscle, with-
out involvement of the venae commitantes of the tibial and
peroneal arteries.7
Despite the fact that a significant percentage of patients
with deep vein thrombosis (DVT) have isolated gastrocne-
mius and soleal vein thrombosis (IGSVT), no treatment
guidelines are available for this variant of DVT, as not even
the natural history of IGSVT has been previously reported.
To begin to better understand the behavior of IGSVT, this
study was designed: 1, to prospectively determine the rate
and timing of progression of untreated IGSVT, with serial
CFDU, over a period of 3 months; and 2, to identify the
risk factors for IGSVT propagation into the deep veins of
the calf and thigh.
PATIENTS AND METHODS
Patient selection. The Sir Mortimer B. Davis Jewish
General Hospital (SMBD-JGH) is a 673-bed tertiary-care
teaching hospital, affiliated with McGill University. The
study was approved by the hospital’s Institutional Review
Board, and recruitment took place from February 14,
1995, to January 22, 1999. All patients had been referred
by a physician to the vascular laboratory at the SMBD-JGH
because of suspected DVT of the lower extremity. Each
patient was prospectively evaluated for IGSVT with color
duplex ultrasonography of both limbs. Patients found to
have thrombosis of any deep venous segment other than an
IGSVT, or undergoing systemic anticoagulation therapy
on first presentation, were excluded, as were patients who
either refused or were unable to comply with the study
design.
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Patient interview and selection. Patient data was
prospectively entered into a computerized database. Pa-
tient age and gender were recorded. Also recorded were the
referring physician’s clinical indication for initial duplex
scan imaging, the ambulatory status of the patient, and the
duration, site, and nature of symptoms, as described by the
patient at the time of the initial duplex scan evaluation.
Finally, five potential risk factors for ISGVT propagation
were prospectively assessed, including: 1, cardiac disease
(documented coronary artery disease, congestive heart fail-
ure, atrial or ventricular arrhythmia); 2, cancer (local or
metastatic); 3, known hypercoagulable state (pregnancy/
postpartum, estrogen supplementation, protein C/S/anti-
thrombin deficiency, factor V Leiden mutation); 4, recent
general/orthopedic/vascular or gynecologic surgery or
trauma (within 3 months of presentation); and 5, venous
disease (varicose veins, previous venous stripping, previous
DVT or superficial thrombophlebitis, previous pulmonary
embolism).
Vascular laboratory examination. All study patients
underwent bilateral lower extremity duplex ultrasound scan
imaging as previously described by our vascular laborato-
ry.17,18 Each patient was evaluated on the first day of
presentation, with repeat examinations of the involved leg
5, 9, 14, 30, and 90 days later. No patient received systemic
anticoagulation therapy. Each patient was followed for 3
months or until the IGSVT progressed or resolved or until
the patient became otherwise ineligible for study. All du-
plex scans were performed by one of two registered vascular
technologists, each with at least 4 years of experience.
Venous imaging was performed on a high-resolution,
real-time B-mode ultrasound scan imager with color flow
capability (ATL-HDI 3000, Bothell, Wash). An 8-MHz
probe with an integrated 5-MHz pulsed Doppler was used.
Most scans took 15 to 30 minutes to complete. Patients
were examined in the reverse Trendelenburg’s position (15
degrees), beginning at the level of the common femoral
vein with procession caudally to the superficial femoral vein
at the level of the adductor canal. The posterior tibial veins
then were identified at the level of the ankle and followed
cephalad to the upper calf, with the patients knees slightly
flexed. Then, with the patient in the prone position with
the knee flexed at 30 degrees, the popliteal, peroneal,
soleal, and gastrocnemius veins were examined. Patients
unable to assume the prone position were examined in the
lateral decubitus position.
DVT was diagnosed on the basis of at least two of the
following criteria: venous incompressibility with probe
pressure, visualization of intraluminal thrombus, lack of
spontaneous venous phasicity, or the absence of flow aug-
mentation with caudal manual compression.7,13 The study
endpoint was defined as CFDU documentation of IGSVT
propagation into the adjacent tibial or peroneal veins or
more proximal veins. IGSVT resolution, regression, and
stabilization were considered to be the same thing (ie, lack
of propagation). Time to propagation or resolution was
noted. Risk factors for propagation were evaluated.
Statistical analysis. Results are reported as propor-
tions or as mean values  standard deviations. In assess-
ment of statistical significance, the Student t test and the 2
analysis were used. P values were two-tailed, with a value of
less than .05 considered to be significant.
RESULTS
Baseline data
Patient demographics. One hundred eighty-five pa-
tients with IGSVT (representing 219 effected limbs) were
enrolled in the study. Thirty-four patients (18%) had bilat-
eral disease. The 83 men (44.9%) and 102 women (55.1%)
were aged 22 to 96 years (mean age, 70.9  15.7 years).
One hundred twenty-seven patients (68.6%) were seen
as inpatients, and 44 patients (23.8%) were ambulatory
outpatients. No patients were receiving nonambulatory
outpatient care. Among inpatients, 121 (65.4%) were re-
ceiving active acute inpatient care, four (2.2%) were receiv-
ing convalescence care, and two (1.1%) received chronic
care. Patient location was not available for 14 patients
(7.6%).
Physician’s reasons for referral. The referring physi-
cian’s clinical indications for referral for CFDU are re-
corded in Table I. Because some patients were seen with
more than one indication for duplex scanning, the total
number of indications for duplex scanning was greater than
the 185 patients enrolled.
Patients symptoms at time of presentation. Pa-
tient’s symptoms at the time of their first duplex scan are
recorded in Table II. Forty-seven enrolled patients (25.4%)
were either too ill or otherwise noncompliant to record
symptoms of pain or swelling. One hundred one patients
(54.6%) enrolled in the study were able to estimate the time
from the onset of symptoms until the initial duplex scan
investigation. The mean duration of symptoms was 9.7 
11.5 days (median, 7 days; minimum, 1 day; maximum, 60
days).
DVT risk factors. Forty-four patients (23.8%) had
cardiac disease. Cancer was present in 36 patients (19.5%),
hypercoagulable states in five (2.7%), recent surgery/
trauma in 85 (45.9%), and prior venous disease in 21
(11.4%).
Site of DVT. On initial duplex scan examination of
185 patients, 219 limbs were found to have IGSVT. The
sites of these IGSVT are presented in Table III. More
right-sided than left-sided IGSVT cases were seen (129
Table I. Clinical indications for initial duplex scan as
documented by referring physician (no. of patients)
Symptoms Right leg Left leg Bilateral
Pain and/or swelling 60 (32.4%) 56 (30.3%) 28 (15.1%)
Other
Suspected pulmonary
embolism
26 (14.1%)
Fever 1 (0.5%)
No clinical indication
recorded
14 (7.6%)
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right versus 90 left; P  .008). Isolated soleal vein throm-
bosis occurred more often on the right side (60/170 left
versus 110/170 right), whereas isolated gastrocnemius
vein thrombosis occurred more often on the left side
(28/42 left versus 14/42 right).
Patient characteristics according to site of DVT.
Patients with soleal vein thrombosis were significantly older
than those with isolated gastrocnemius vein thrombosis
(73.1 versus 64.8 years; P  .002). No statistically signifi-
cant difference was seen on the basis of the gender of the
patient in regards to site at presentation (P  .11).
Among inpatients, 86.7% of DVTs were soleal and
13.3% were gastrocnemius, compared with outpatients
where 61.1% were soleal and 38.9% were gastrocnemius
(P  .003). No differences were seen in the presence of
cardiac disease, cancer, hypercoagulable states, surgery/
trauma, prior venous disease, or prevalence of pain and
swelling according to site of DVT.
Follow-up data
One-month and 3-month follow-up. Among the
185 patients found to have IGSVT on initial duplex scan-
ning, 120 patients (64.9%)—representing 135 limbs—
were followed with serial duplex scans for 3 months or until
IGSVT progression was found to the adjacent tibial or
peroneal veins or the deep veins of the upper leg. From this
group, 100 patients (83.3%) initially were seen with unilat-
eral ISGVT and 20 (16.7%) initially were seen with bilateral
ISGVT.
For 18 patients, complete data were available at 1
month, but not at 3 months, representing 20 limbs. Forty-
seven patients were lost to follow-up within 1 month of the
study period. Complete data were available for 120 patients
(64.9%) at 3 months, representing 135 limbs. Full 3-month
follow-up was not available for 65 of the patients (35.1%)
enrolled in the study. Eighty-four limbs were lost to the
study by the 3-month follow-up for the following reasons:
attending physician anticoagulation therapy contrary to
study protocol (n  11), patient death (n  22), patient
relocation to another city (n 1), patient refusal to further
follow-up (n  5), withdrawal from the study by the
referring physician for unspecified reasons (n  3), inap-
propriate cessation of duplex scan monitoring from resolu-
tion of a contralateral thrombus (n  1), anticoagulation
therapy of a propagation of a contralateral thrombus (n 
2; one to the popliteal vein and one to a peroneal vein), and
interhospital transfer (n  4). Thirty-five other limbs were
lost from the study, not because the patient died or was
definitively removed from the study (for the reasons cited
previously) but because the patient missed one or more
follow-up appointments because of temporary ill health,
forgetfulness, or transportation problems. These patients
became ineligible for 3-month follow-up analysis.
Comparison of characteristics of those who com-
pleted 3-month follow-up versus those who did not.
Patients who successfully completed the 3-month fol-
low-up protocol were significantly younger than those who
did not do so (67.3 versus 77.4 years; P .0001). Patients
without a 3-month follow-up were more likely to have
cardiac disease (33.8% versus 18.3%; P  .018) and cancer
(27.7% versus 15%; P  .037) than those with a full
3-month follow-up. Chronic venous disease was more
common in patients with full 3-month follow-up than in
those without 3-month follow-up (15% versus 4.6%; P 
.033).
Location of thrombi. Of the 135 limbs followed for 3
months, at baseline, 105 limbs (77.8%) contained throm-
bus isolated to the soleal vein, 27 (20%) had thrombi
isolated to the gastrocnemius vein, and three (2.2%) had
thrombus isolated to both the gastrocnemius and soleal
veins.
Course of IGSVT. Of the 135 limbs with IGSVT that
were followed for 3 months, complete thrombus resolution
had occurred in 13 (9.6%) within 2 weeks, in 28 (20.7%)
Table II. Patient symptoms at time of presentation for initial duplex scan (no. of patients)
Symptoms Right leg Left leg Bilateral
Pain 34 (18.4%) 26 (14.1%) 5 (2.7%)
Swelling 10 (5.4%) 16 (8.6%) 12 (6.5%)
Pain and swelling 12 (6.5%) 10 (5.4%) 1 (0.5%)
Other
Left pain/right swelling 1 (0.5%)
Asymptomatic 11 (5.9%)
No data available 47 (25.4%)
Table III. Site of IGSVT diagnosed on initial duplex scan (no. of patients)
Gastrocnemius Soleus
Gastrocnemius
and soleus
Left 28 (12.8%) 60 (27.4%) 2 (0.9%)
Right 14 (6.4%) 110 (50.2%) 5 (2.3%)
Total 42 (19.2%) 170 (77.6%) 7 (3.2%)
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within 4 weeks, and in 62 (45.9%) within 3 months of
duplex scanning. A further 51 limbs (37.7%) with IGSVT
remained stable or partially resolved over that time. In total,
IGSVT in 113 of 135 limbs remained stable or resolved
without anticoagulant treatment during the 3-month fol-
low-up.
Twenty-two of the 135 limbs with IGSVT (16.3%)
extended their thrombus to the level of the adjacent tibial
or peroneal veins or higher within the 3-month study
period. The great majority (20/22; 90.9%) of thrombus
extensions occurred within 2 weeks of the initial duplex
scan. Among patients who did not have extension of
IGSVT by the day 14 duplex scan, no thrombus extensions
were detected at the day 30 duplex scan, although two
patients were found to have extension of thrombi at the day
90 duplex scan (2/22 late extensions; 9%). No late propa-
gation extended as far as the popliteal vein. One such
patient, a 53-year-old woman with a history of cancer,
originally had a right gastrocnemius DVT that extended to
the tiboperoneal trunk of the right leg. The second patient,
an 84-year-old woman with a history of surgery/trauma,
originally had a left soleal DVT that extended to the pero-
neal vein of the left leg.
Of the 22 limbs with IGSVT propagation, the most
proximal level of clot extension was the peroneal vein in 16
limbs, the posterior tibial vein in one limb, the tibiopero-
neal trunk in one limb, and the popliteal vein in four limbs.
Hence, in the entire study population that was followed for
3 months, only 4/135 limbs (2.9%) extended their throm-
bus to the level of the popliteal vein. No IGSVT propagated
to a venous segments more cephalad than the popliteal
vein.
Gastrocnemius vein thrombi appeared to be more
prone to propagate than those involving the soleal veins
(7/27 or 25.9% versus 15/105 or 14.3%), but this differ-
ence was not statistically significant (P .15). The peroneal
vein was the most proximal vein involved in 71% of propa-
gating thrombi originating from the gastrocnemius vein
and in 73% of thrombi extending from the soleal vein. No
combined gastrocnemius and soleal vein thrombosis ex-
tended into the adjacent veins of the calf. The side of the
initial IGSVT was not predictive of propagation (nine on
the left and 13 on the right; P  .072).
Patient characteristics predictive of progression.
Neither age, gender, inpatient/outpatient status, referring
physician’s clinical indications for scanning, nor nature of
the presenting symptoms predicted extension of IGSVT.
Of the patient comorbid risk factors for IGSVT, only the
presence of cancer, either regional or metastatic, was found
to be prognostic of IGSVT propagation (7/22 with pro-
gression had cancer versus 14/133 without progression;
P  .02). However, the presence of cancer was not prog-
nostic of thrombus extension beyond the deep veins of the
calf. Neither cardiac disease, hypercoagulable states, recent
surgery/trauma, nor prior venous disease proved prognos-
tic for IGSVT propagation.
DISCUSSION
Given the rapid advances in its resolution and wide-
spread availability, CFDU has supplanted contrast venog-
raphy as the imaging method of choice for diagnosis of
CVT, including thrombosis involving the veins draining
the gastrocnemius and soleal muscles. The vascular labora-
tory at SMBD-JGH has compared contrast venography
with CFDU at both the femoral and tibioperoneal levels,
documenting a sensitivity of 94% and a specificity of 99% for
duplex scanning in detection of DVT.17 CFDU has else-
where been reported to have a diagnostic sensitivity of 94%
to 100%, specificity of 91% to 100%, positive predictive
value of 80%, and negative predictive value of 94% for
detection of DVT at the level of the tibial and peroneal
veins.3,4,7,9,13,16,19 Compared with contrast venography,
CFDU has an overall sensitivity, specificity, and accuracy of
greater than 87% at the level of the gastrocnemius and
soleal veins.7
With these advances in CFDU technology, IGSVT is
being diagnosed with increasing frequency. In a recent
prospective study of 5250 patients with suspected DVT,
acute DVT was documented with CFDU in 14% of pa-
tients, with 4.8% of patients with thrombi isolated to the
veins of the calf. Forty percent of these isolated CVT were
isolated to the veins draining the gastrocnemius and soleal
muscles.7 Therefore, approximately 2% of all symptomatic
patients scanned with CFDU to rule out DVT were found
to have IGSVT. Despite the significant number of patients
with diagnosis of symptomatic IGSVT, little is known with
regards to the natural history or management of this variant
of CVT.
Once diagnosed, IGSVT presents clinicians with a new
management dilemma. Such thrombosis theoretically poses
a risk of progression into the larger veins of the leg, with the
possible sequelae of pulmonary embolism or venous in-
competence. However, published recommendations for
the treatment of CVT are based almost exclusively on the
observed natural history of CVT involving the venae com-
mitantes of the named tibial and peroneal arteries of the
calf. Aside from these recommendations being far from
uniform, extrapolation of the present treatment guidelines
for CVT to the treatment of IGSVT may not be warranted
if the natural histories of IGSVT and tibioperoneal vein
thrombosis are distinctly different.3,4,6,8,10
Our study has shown that the rate of IGSVT propaga-
tion beyond the level of the calf is much less than that
previously reported for CVT other than IGSVT. Over the
3-month study period, IGSVT propagation to the level of
the tibioperoneal veins occurred in 16.3% of patients, with
only 2.9% of IGSVT propagating as far as the popliteal vein.
No IGSVT propagated beyond the popliteal vein. Previ-
ously reported prospective studies have described CVT
(not IGSVT) propagation rates of 28% to 32%, with 11% to
15% propagating to the level of the popliteal vein or high-
er.3,4 IGSVT and tibioperoneal vein thrombosis do behave
in a similar fashion with regard to the timing of thrombus
propagation and regression. We found that 90.9% of
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IGSVT propagation occurred within 2 weeks of CFDU
documentation. Although progression of IGSVT did occur
beyond 2 weeks (at 90 days in two patients), it was not
associated with clot extension beyond the calf. IGSVT
regression was not as rapid as propagation, although almost
half of documented IGSVT were found to be fully resolved
within 3 months of diagnosis. In previous studies, no CVT
propagation was noted to occur more than 2 weeks after
diagnosis, with 88% of CVT being completely resolved
within 3 months of diagnosis.6,13
Therefore, IGSVT seems to be more benign than tibial
and peroneal vein thrombosis with respect to their level of
propagation but seems to be comparable in the time frame
in which they propagate and resolve. No conclusions can be
drawn from this study regarding the benefit of systemic
anticoagulation therapy versus expectant management of
IGSVT. This was not the purpose of this study. It is
interesting to note that systemic heparinization of tibial and
peroneal vein thrombi has not been found to influence
thrombus extension or regression.4,6,10,13 However, appli-
cation of previously reported guidelines for the treatment
of CVT, toward the treatment of IGSVT, should be dis-
couraged. IGSVT appears to be a separate disease entity
that requires more study and quite possibly a different
treatment regime than CVT, perhaps, even, no treatment at
all.
Limitations of study. This study had 35.1% failure
rate for follow-up at 3 months. Twenty-two patients died
during this study. Although none of these deaths were
known to be from thromboembolic events, post mortem
examinations were not a part of the study protocol, so death
from thromboembolism could not be definitively excluded.
Furthermore, although 113 of 135 IGSVT remained stable
or resolved without anticoagulant treatment during this
study, delayed propagation of the incompletely lysed
thrombi cannot be excluded beyond the relatively short
study period of 3 months.
CONCLUSION
Untreated IGSVT propagated to the level of the pop-
liteal vein in 3% of limbs followed over the 3-month study
period, all within 2 weeks of initial CFDU diagnosis. This is
a much lower rate than previously reported for tibial and
peroneal vein thrombi. No thrombi extended beyond the
popliteal vein. Only the presence of cancer was found to be
prognostic of IGSVT propagation, but it was not prognos-
tic of propagation beyond the level of the calf. Although the
study period was of a short duration, repeated CFDU
imaging to assess for IGSVT propagation beyond 14 days
of initial diagnosis is likely unnecessary and not cost effec-
tive.
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